Literature DB >> 8404921

In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).

T U Westblom1, B R Midkiff, S J Czinn.   

Abstract

The in vitro activity of trospectomycin, pirlimycin, mirincamycin and N-demethyl clindamycin was measured against 46 clinical isolates of Helicobacter pylori using an agar dilution technique. The MIC50 and MIC90 were 4 and 64 micrograms/ml for pirlimycin and N-demethyl clindamycin, and 32 and 128 micrograms/ml for mirincamycin, respectively. All 46 strains were sensitive to trospectomycin with an MIC50 of 8 micrograms/ml and an MIC90 of 16 micrograms/ml. Of seven strains with the highest trospectomycin MICs (8 or 16 micrograms/ml) 100% were found to be resistant to metronidazole. Among ten strains with low trospectomycin MICs (2 micrograms/ml or less) 100% were sensitive to metronidazole. Possible explantations for the apparent correlation between the MICs of the two drugs are discussed. Since all metronidazole resistant strains were sensitive to trospectomycin, this drug may be useful in treating infection with metronidazole resistant Helicobacter pylori.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8404921     DOI: 10.1007/bf01970966

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  In vitro effect of metronidazole on the ultrastructure of Trichomonas vaginalis donné.

Authors:  M H Nielsen
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-04

2.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

Review 3.  Helicobacter pylori therapy: effect on peptic ulcer disease.

Authors:  A T Axon
Journal:  J Gastroenterol Hepatol       Date:  1991 Mar-Apr       Impact factor: 4.029

4.  In vitro activity of U-57930E, a new clindamycin analog, against aerobic gram-positive bacteria.

Authors:  V I Ahonkhai; C E Cherubin; M A Shulman; M Jhagroo; U Bancroft
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  In vitro activity of U-57930E against anaerobic bacteria and its comparison with clindamycin, ampicillin, carbenicillin and tetracycline.

Authors:  S M Qadri; M R Karim; D J Flournoy
Journal:  J Antibiot (Tokyo)       Date:  1983-01       Impact factor: 2.649

6.  Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens.

Authors:  T U Westblom; D E Duriex; E Madan; R B Belshe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Enhancement of the curative activity of primaquine by concomitant administration of mirincamycin.

Authors:  L H Schmidt
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

8.  Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture.

Authors:  A A Divo; T G Geary; J B Jensen
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

9.  Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  The mechanism of formation of inhibitor-induced ribosome helices in Entamoeba invadens.

Authors:  T Kusamrarn; P Sobhon; G B Bailey
Journal:  J Cell Biol       Date:  1975-06       Impact factor: 10.539

View more
  3 in total

1.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

2.  In vitro activities of new quinolones against Helicobacter pylori.

Authors:  M Carbone; M T Fera; V Cecchetti; O Tabarrini; E Losi; V Cusumano; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

3.  Absolute bioavailability of cis-mirincamycin and trans-mirincamycin in healthy rhesus monkeys and ex vivo antimalarial activity against Plasmodium falciparum.

Authors:  Phisit Khemawoot; David Saunders; Maneerat Rasameesoraj; Victor Melendez; Rawiwan Imerbsin; Colin Ohrt; Susan Fracisco; Paktiya Teja-Isavadharm
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.